Sign in

CIK 0001664710

  • Non-accelerated filer
  • Smaller reporting company

Keros Therapeutics, Inc.

Sign in to watch
Ticker
KROS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
811173868
Phone
+1 617-314-6297
Business address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
  1. 4 Option exercise Director acquired 7,176 shares (option exercise)
  2. 3/A Insider 3/A
  3. 3/A Insider 3/A
  4. 3/A Insider 3/A
  5. 4 Open-market sale Chief Scientific Officer sold 46,034 shares at $30.00 ($1,381,020)
  6. 4 Open-market sale Chief Scientific Officer sold 1,916 shares at $30.00 ($57,480)
  7. 4 Option exercise Chief Scientific Officer acquired 9,400 shares (option exercise)
  8. 4 Option exercise Chief Executive Officer acquired 5,000 shares (option exercise)
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Open-market sale Chief Scientific Officer sold 5,300 shares at an average $41.90 ($222,050)
  16. 4 Open-market sale Chief Scientific Officer sold 5,300 shares at an average $62.77 ($332,705)
  17. 4 Open-market sale Chief Operating Officer sold 1,728 shares at $65.00 ($112,320)
  18. 4 Open-market sale Chief Scientific Officer sold 7,950 shares at $60.00 ($477,000)
  19. 4 Open-market sale Chief Operating Officer sold 864 shares at an average $57.49 ($49,675)
  20. 4 Open-market sale Chief Scientific Officer sold 2,650 shares at an average $53.38 ($141,449)

Page 6 of 11 · 207 filings